Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 CAR-T in R/R T-ALL and T-LBL
NCT04860817Phase 1Withdrawn
- Start
- Dec 2021
- Primary completion
- Apr 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD7 CAR-T cells injection in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Primary endpoint: Number of patients with dose-limiting toxicity at 4 weeks. Planned start Dec 2021; status: withdrawn.
02
Drugs
CD7 CAR-T cells injection
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT04860817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860817.